Group 1 - The report outlines the key points from four phone calls between Chinese President Xi Jinping and U.S. President Trump, emphasizing the importance of maintaining stable and cooperative U.S.-China relations [5][4]. - In the first call on January 17, 2025, President Xi congratulated Trump on his re-election and highlighted the broad common interests and cooperation potential between the two countries [5]. - The second call on June 5, 2025, focused on correcting the course of U.S.-China relations and emphasized the importance of dialogue and cooperation in resolving trade issues [5]. Group 2 - The third call on September 19, 2025, recalled the historical alliance during World War II and urged the U.S. to avoid unilateral trade restrictions that could undermine previous negotiations [5]. - The fourth call on November 24, 2025, discussed the positive outcomes of the recent meeting in Busan and reiterated the mutual benefits of cooperation, while also addressing the Taiwan issue as a critical aspect of China's sovereignty [5][4]. - Throughout the calls, both leaders expressed a desire for continued dialogue and cooperation to address global challenges, including the Ukraine crisis [5].

Report Industry Investment Rating No information provided in the given content. Core Viewpoints of the Report - The market is oscillating downward, with major broad - based indexes generally declining. A - share, Hong Kong, and US major broad - based ETFs, as well as commodity ETFs like gold, have all seen drops. Most major industry ETFs in the A - share market have also declined, especially in the advanced manufacturing sector [11]. - In terms of index product trends, 19 index products were established, 14 ended their fundraising, 8 started fundraising, and 29 were newly declared, with 7 ETFs in the science - innovation chip direction being concentratedly declared [1][5][7][9]. - Regarding ETF fund flows, the total market scale decreased compared to the previous week. Among non - currency ETFs, ETFs targeting Hang Seng Technology had the largest net inflow, while those targeting CSI Banks had the largest net outflow [22][25]. Summary by Directory 1. Index Product Establishment, Fundraising, and Declaration - **Product Establishment and Listing**: Four ETF products, including Southern Hang Seng Technology ETF and Southern CSI Hong Kong Stock Connect High - Dividend Investment ETF, were listed, and 19 products, such as Penghua Hang Seng Technology ETF and Huaxia S&P Hong Kong Stock Connect Low - Volatility Dividend ETF, were established [1][5]. - **Product Issuance Information**: Fourteen index products, like Xingyin China Securities New Energy Vehicle Battery ETF Linked A, will end their fundraising in the coming week, and 8 products, such as Dacheng CSI 800 Index Enhancement A, will start fundraising [7][8]. - **Product Declaration Information**: A total of 29 index products were declared in the past week, with 7 ETFs in the science - innovation chip direction being concentratedly declared by multiple fund companies, including E Fund and Penghua [1][9]. 2. ETF Market Review - **Broad - based ETFs**: A - share major broad - based ETFs generally declined, with higher drops in Science and Technology Innovation 50 ETF, CSI 500 ETF, and ChiNext 50 ETF. Hong Kong and US major broad - based ETFs also had significant drops. Gold ETF dropped by 2.50% [11]. - **Industry ETFs**: Most major industry ETFs in the A - share market declined. The advanced manufacturing sector had a relatively high decline, with the Photovoltaic ETF dropping the most at - 11.19%, and the New Energy Vehicle ETF and Battery ETF dropping by - 8.28% and - 9.56% respectively. The Steel ETF in other categories dropped by - 7.13% [13]. - **Cross - border ETFs**: Cross - border market major broad - based indexes oscillated downward, with the China - South Korea Semiconductor index dropping the most at - 6.32%. The Huatai - Peregrine CSI Korea Exchange China - South Korea Semiconductor ETF dropped by 10.06% [15]. 3. ETF Fund Flows - **Market Scale**: As of November 21, 2025, there were 1304 ETFs in the entire market, with a total scale of 55004.93 billion yuan, a decrease of 1318.36 billion yuan from the previous week. A - share and cross - border ETFs ranked first and second in scale, with the A - share ETF scale decreasing by 1175.02 billion yuan [22]. - **Net Inflow and Outflow**: Among non - currency ETFs, ETFs targeting Hang Seng Technology had the largest net inflow of 92.52 billion yuan, while those targeting CSI Banks had the largest net outflow of 16.76 billion yuan. Southern CSI 500 ETF and E Fund ChiNext ETF had relatively high inflows of 57.32 billion and 46.35 billion yuan respectively [25][27]. - **Liquidity**: Haifutong CSI Short - Term Financing ETF led in liquidity, with an average daily trading volume of 194.00 billion yuan in the past week. Huaxia Shanghai Stock Exchange Benchmark Market - Making Treasury Bond ETF also had high liquidity, with an average daily trading volume of 111.58 billion yuan [27].

Investment Rating - The report maintains a "Buy" rating for ZTO Express (02057) [2] Core Views - The company reported a Q3 2025 revenue of 11.865 billion yuan, a year-on-year increase of 11.1%, and an adjusted net profit of 2.506 billion yuan, up 5% year-on-year, aligning with expectations [7] - The report highlights that the company's volume and profit both increased in Q3, driven by industry-wide efforts to reduce competition and improve pricing, suggesting continued improvement in Q4 [7] - The report notes a downward trend in the express delivery industry's growth rate, with ZTO Express expected to gain market share and improve profitability amid increasing industry differentiation [7] - The profit forecast for ZTO Express has been raised, with adjusted net profit estimates for 2025-2027 now at 9.54 billion, 10.15 billion, and 11.40 billion yuan respectively, reflecting a year-on-year growth of -6%, 6%, and 12% [7] Financial Data and Profit Forecast - Revenue projections for ZTO Express are as follows: - 2023: 38.419 billion yuan - 2024: 44.281 billion yuan - 2025E: 48.669 billion yuan - 2026E: 54.593 billion yuan - 2027E: 61.181 billion yuan - Adjusted net profit forecasts are: - 2023: 9.006 billion yuan - 2024: 10.150 billion yuan - 2025E: 9.540 billion yuan - 2026E: 10.149 billion yuan - 2027E: 11.399 billion yuan - The report indicates a net asset return rate of 14.52% for 2023, projected to decline to 13.33% in 2024, before gradually increasing to 15.27% by 2027 [6][7]

Investment Rating - The report suggests a positive outlook for the automotive industry, particularly focusing on technology-driven companies and the robotics supply chain [5][6]. Core Insights - The automotive sector is experiencing a rebound, with significant developments in the robotics industry and related companies. The report highlights the low expectations currently priced into the stocks of these companies, despite ongoing advancements in the industry [5][6]. - The report emphasizes the importance of technology and high-end products, predicting a substantial increase in demand for new B/C class vehicles, driven by changes in consumer habits and product competitiveness [6][7]. - The report identifies key players in the market, including NIO, Xiaomi, and XPeng, and suggests that companies with strong performance and low valuations, such as KOBODA and Xingyu, should be closely monitored [5][6]. Market Updates - According to the latest data from the China Passenger Car Association, the average daily retail sales of passenger cars in the second week of November were 67,000 units, a year-on-year decrease of 9% [5][6]. - The total transaction value in the automotive industry for the week was 421.1 billion yuan, reflecting an 18.56% decrease compared to the previous week [5][11]. - The automotive industry index closed at 7308.64 points, down 4.89% for the week, which is a larger decline compared to the Shanghai Composite Index [11][14]. Key Events - The Guangzhou Auto Show showcased a significant shift in the competitive landscape of the automotive industry, with over 20 brands absent, indicating increased pressure on weaker brands [8][10]. - The report notes that the focus of competition has shifted from individual models to technological ecosystems, with companies emphasizing their comprehensive capabilities in technology and supply chain integration [10][11]. Company Performance - The report highlights that 20 stocks in the automotive sector rose while 251 fell, with the largest gainers being Tianpu Co., Luochang Technology, and Zhejiang Rongtai, which saw increases of 14.7%, 8.1%, and 7.6% respectively [17][19]. - The report also mentions that the automotive industry’s price-to-earnings ratio stands at 27.25, ranking it 19th among all sectors, indicating a moderate valuation level [14][16]. Future Outlook - The report anticipates that the globalization of Chinese electric vehicles will accelerate, with expectations of nearly 10 million units sold overseas within five years [6][7]. - The report underscores the dual transformation of the automotive industry towards electrification and AI integration, predicting that AI will play a crucial role in enhancing driving experiences and operational efficiencies [7][8].

Investment Rating - The report maintains a positive outlook on the automotive industry, highlighting potential investment opportunities in technology-driven companies and the robotics supply chain [5][6]. Core Insights - The automotive industry is experiencing a rebound, particularly in the robotics sector, with companies like Tesla and Xpeng leading the way. The report suggests focusing on technology leaders and related robotics companies [5][6]. - The report emphasizes the importance of the upcoming 2026 timeline for the realization of technological advancements in the automotive sector, particularly in electric vehicles and AI integration [6][7]. - The report notes a significant decline in average daily retail sales of passenger vehicles, down 9% year-on-year, indicating a challenging market environment [5][51]. - The Guangzhou Auto Show showcased a shift in competition from individual models to comprehensive technology ecosystems, reflecting the industry's evolution towards system-level competition [10][24]. Industry Updates - The report indicates that the average daily retail sales of passenger vehicles in the second week of November were 67,000 units, a decrease of 9% compared to the same period last year [5][51]. - The automotive industry index fell by 4.89% this week, underperforming compared to the Shanghai Composite Index, which declined by 3.77% [11][14]. - The report highlights that 20 stocks in the automotive sector rose while 251 fell, with the largest gainers being Tianpu Co., Luochang Technology, and Zhejiang Rongtai [17][19]. Market Conditions - The total transaction value in the automotive sector for the week was 421.1 billion yuan, reflecting an 18.56% decrease from the previous week [5]. - The report notes a decrease in both traditional and new energy raw material price indices, indicating potential cost pressures for manufacturers [5]. - The report identifies key events, including the Guangzhou Auto Show, which highlighted the acceleration of brand clearing and systemic competition in the automotive market [8][9]. Investment Recommendations - The report recommends focusing on domestic leading manufacturers such as NIO, Xiaomi, and Xpeng, as well as component companies with strong performance and growth potential [5][6]. - It suggests that companies with strong performance growth and capabilities in robotics or overseas expansion, such as Xingyu Co., Fuyao Glass, and Newquay Co., should be closely monitored [5][6]. - The report also emphasizes the importance of state-owned enterprise reforms and their potential impact on companies like SAIC and Dongfeng [5].

Core Insights - The report highlights Qingmu Technology (青木科技) as a leading expert in full-domain operation services and brand incubation, driven by data and technology [2][4][14] - The company has established a high-synergy business model encompassing operation services, brand incubation, and technical solutions, serving well-known brands across various sectors [2][4][14] - Financial projections indicate significant revenue growth, with expected revenues of 15.1 billion, 19.0 billion, and 23.4 billion yuan for 2025 to 2027, representing year-on-year growth rates of 30.5%, 26.5%, and 23.0% respectively [4][14] Company Overview - Qingmu Technology was founded in 2009 and has focused on e-commerce operation since 2011, building a comprehensive service model that includes operation, brand incubation, and technology solutions [2][14] - The company has a stable ownership structure, with founders holding 39% of the shares, and a management team with over ten years of industry experience [2][14] - Revenue for 2024 and the first half of 2025 is projected at 1.15 billion and 670 million yuan, with year-on-year growth rates of 19.2% and 22.75% respectively [2][14] Competitive Advantages - Qingmu Technology's competitive edge lies in its data, technology, and brand matrix, which collectively enhance its operational value [3][4][14] - The data layer includes services across major platforms like Tmall, JD.com, Douyin, and Xiaohongshu, allowing the company to accumulate extensive user behavior and transaction data [3][14] - The technology layer features proprietary systems such as the Qingling AI platform and CRM, which streamline operations and reduce costs [3][14] Business Model and Growth Strategy - The company is expanding its service model from a single service fee to a combination of service fees, distribution price differences, and equity returns, thus sharing in brand growth [4][14] - Qingmu Technology is diversifying its product categories beyond apparel to include trendy toys, beauty products, health consumer goods, and pet food, enhancing its growth potential [4][14] - The company aims to maintain its status as a top service provider on platforms like Tmall and Douyin while increasing its international operations, particularly in Southeast Asia [4][14] Financial Projections - The report forecasts a steady increase in net profit, with expected figures of 1.31 billion, 1.85 billion, and 2.59 billion yuan for 2025 to 2027, reflecting growth rates of 45.2%, 40.4%, and 40.4% respectively [4][14] - The projected price-to-earnings (PE) ratios for the same period are 50, 35, and 25 times, indicating a favorable valuation outlook [4][14]

Investment Rating - The report maintains a "Buy" rating for CSPC Pharmaceutical [8][14] Core Views - CSPC Pharmaceutical reported a revenue of RMB 19.89 billion for the first three quarters of 2025, a decrease of 12.3% year-on-year, with a net profit of RMB 3.51 billion, down 7.1% year-on-year. However, the third quarter showed signs of recovery with a revenue increase of 3.4% year-on-year to RMB 6.62 billion and a net profit increase of 27.2% year-on-year to RMB 964 million, aligning with expectations [5][10] - The company's gross margin decreased by 4.9 percentage points year-on-year to 65.6% in the first three quarters of 2025, with the sales contribution from finished drugs dropping from 82.3% to 77.7% [10][11] - The report highlights a significant decline in oncology product sales, which fell by 56.8% year-on-year to RMB 1.65 billion, representing only 10.7% of total finished drug sales [11] - CSPC has made progress in its innovative pipeline, with 28 key products in pivotal clinical trials and an increase in R&D expenses by 7.9% year-on-year to RMB 4.19 billion, reflecting a commitment to innovation [8][13] Financial Summary - For 2025, the company expects a revenue of RMB 26.785 billion, a decrease of 7.67% year-on-year, and a net profit of RMB 4.559 billion, with an EPS forecast adjusted down to RMB 0.40 [9][14] - The report projects a target price adjustment from HKD 12.7 to HKD 9.7, indicating a potential upside of 31% [14]

Investment Rating - The report maintains a "Buy" rating for CSPC Pharmaceutical [1][14] Core Views - The company reported a 12.3% year-on-year decline in revenue for the first three quarters of 2025, totaling RMB 19.89 billion, while net profit decreased by 7.1% to RMB 3.51 billion. However, in the third quarter, revenue grew by 3.4% year-on-year to RMB 6.62 billion, and net profit increased by 27.2% to RMB 964 million, aligning with expectations [4][10] - The gross margin decreased by 4.9 percentage points year-on-year to 65.6%, with the sales contribution from finished drugs dropping from 82.3% in the first three quarters of 2024 to 77.7% in 2025 [4][10] - The company has a robust pipeline with 28 key products in pivotal clinical trials and a significant increase in R&D expenses, which rose by 7.9% year-on-year to RMB 4.19 billion, representing 21.0% of revenue [7][13] Financial Performance - For the first three quarters of 2025, finished drug sales fell by 17.3% year-on-year to RMB 15.45 billion, but third-quarter sales returned to growth at RMB 5.20 billion, up 1.6% year-on-year [5][11] - The oncology product sales saw a significant decline of 56.8% year-on-year to RMB 1.65 billion, now representing 10.7% of total finished drug sales [5][11] - The API segment experienced a 22.3% year-on-year increase in vitamin C revenue to RMB 1.79 billion, while antibiotic API revenue slightly declined by 3.7% due to price drops [5][11] Pipeline Development - The company is advancing multiple trials for SYS6010 (EGFR ADC), which has received Fast Track Designation from the FDA and Breakthrough Therapy Designation from the NMPA, with data readouts expected in 2026 [6][12] - The innovative pipeline includes 28 products in phase II/III trials, nine in phase II, and approximately 40 in phase I, covering both oncology and non-oncology areas [7][13] Earnings Forecast - The earnings per share (EPS) forecast for 2025 has been adjusted down from RMB 0.46 to RMB 0.40, with target prices revised from HK$12.7 to HK$9.7, indicating a potential upside of 31% [14]

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook based on its performance and growth potential [9]. Core Insights - The company has demonstrated significant growth in IP-derived revenue, which has more than doubled, alongside diversified exploration in its performance business [2][9]. - For FY26H1, the company reported a revenue of 4.05 billion RMB, a year-on-year increase of 33%, and a net profit attributable to shareholders of 520 million RMB, reflecting a 54% growth [6][9]. - The adjusted EBITDA for FY26H1 was 550 million RMB, showing a 14% increase after excluding a one-time financial asset impairment reversal from FY25H1 [6][9]. Financial Data and Profit Forecast - The company’s revenue projections for FY2024 to FY2028 are as follows: - FY2024: 5.036 billion RMB (YoY +43%) - FY2025: 6.702 billion RMB (YoY +33%) - FY2026E: 8.510 billion RMB (YoY +27%) - FY2027E: 9.982 billion RMB (YoY +17%) - FY2028E: 11.336 billion RMB (YoY +14%) [8][10]. - Net profit attributable to ordinary shareholders is forecasted to grow significantly, with FY2026E projected at 1.043 billion RMB, a 187% increase from FY2025 [8][10]. - The report highlights an improvement in management efficiency, with a decrease in management expense ratio to 16.5% in FY26H1, down 3.1 percentage points year-on-year [9]. Business Segments Performance - The IP-derived business segment saw a revenue of 1.16 billion RMB in FY26H1, up 105% year-on-year, with a gross profit of 230 million RMB, reflecting a 44% increase [9]. - The performance segment generated 1.34 billion RMB in revenue, a 14.5% increase year-on-year, with a segment profit of 750 million RMB, up 4.7% [9]. - The film segment reported a revenue of 1.06 billion RMB in FY26H1, a decrease of 15% year-on-year, while the series production segment turned profitable with a revenue of 480 million RMB [9].

Investment Rating - The report maintains a "Buy" rating for the company [5][11]. Core Insights - The company has demonstrated significant growth in IP revenue, with a more than doubling of income from IP-related businesses, particularly in ToB licensing and a rapidly developing ToC segment [11]. - The company's total revenue for FY26H1 reached 4.05 billion RMB, representing a year-on-year increase of 33%, while net profit attributable to shareholders was 520 million RMB, up 54% [8][11]. - The report highlights a strategic shift in the film investment approach, focusing on lower-risk, high-quality content, while the live performance segment is expanding both domestically and internationally [11]. Financial Data and Profit Forecast - The company’s revenue projections for FY2024 to FY2028 are as follows: - FY2024: 5.036 billion RMB (YoY +43%) - FY2025: 6.702 billion RMB (YoY +33%) - FY2026E: 8.510 billion RMB (YoY +27%) - FY2027E: 9.982 billion RMB (YoY +17%) - FY2028E: 11.336 billion RMB (YoY +14%) [10][12]. - Net profit attributable to ordinary shareholders is forecasted to grow significantly, with estimates of 1.043 billion RMB for FY2026E, reflecting a 187% increase from FY2025 [10][12]. - The report anticipates a steady increase in earnings per share, projected to reach 3.52 RMB in FY2026E [10][12]. Business Segment Performance - The IP derivative business saw a revenue increase of 105% in FY26H1, with a focus on high-quality IPs and expanding retail brand operations [11]. - The live performance segment generated 1.34 billion RMB in revenue for FY26H1, marking a 14.5% increase, despite some pressure on profit margins due to international expansion efforts [11]. - The film segment reported a revenue decline of 15% in FY26H1, prompting a strategic pivot towards lower-budget, high-quality films [11].